These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 199059)

  • 1. Antibodies to Epstein-Barr virus capsid antigen and early antigen in nasopharyngeal carcinoma and comparison groups.
    Lin TM; Yang CS; Chiou JF; Tu SM; Chen TY; Tu YC; Lin PJ; Kawamura A; Hirayama T
    Am J Epidemiol; 1977 Oct; 106(4):336-9. PubMed ID: 199059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG and IgA antibodies to Epstein-Barr virus in nasopharyngeal carcinoma patients.
    Gong SH; Lynn TC; Yang CS
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1978 Mar; 11(1):8-15. PubMed ID: 211015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
    Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
    Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
    Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
    Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
    Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
    Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Epstein-Barr virus antigens and antibodies by peroxidase-labeled specific immunoglobulins.
    Kurstak E; de Thé G; van den Hurk J; Charpentier G; Kurstak C; Tijssen P; Morisset R
    J Med Virol; 1978; 2(3):189-200. PubMed ID: 212523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia.
    Dölken G; Bross KJ; Hecht T; Brugger W; Löhr GW; Hirsch FW
    Int J Cancer; 1986 Jul; 38(1):55-9. PubMed ID: 3013785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
    Henle G; Henle W
    Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
    Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
    Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
    PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
    Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
    J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.
    Wong MM; Lye MS; Cheng HM; Sam CK
    Asian Pac J Allergy Immunol; 2005 Mar; 23(1):65-7. PubMed ID: 15997877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies on immunity to EBV-associated antigens in NPC patients in North America, Tunisia, France and Hong Kong.
    Levine PH; Wallen WC; Ablashi DV; Granlund DJ; Connelly R
    Int J Cancer; 1977 Sep; 20(3):332-8. PubMed ID: 198381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.